SIGA Technologies Inc (SIGA) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses...

Form 8-K - Current report

Form 8-K - Current report

Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced

Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024

Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million...

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage...

SIGA Announces Agreement to Supply TPOXX® in Morocco

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) --  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a...

Form 8-K - Current report